Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathy
AIM:To discuss the effect of ranibizumab combined with vitrectomy(VT)on the serum vascular endothelial growth factor A(VEGF-A)and human stromal cell derived factor 1(SDF-1)expression in patients with PDR.<p>METHODS: Totally 120 patients with PDR were selected from January 2017 to January 2018...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2019-03-01
|
Series: | Guoji Yanke Zazhi |
Subjects: | |
Online Access: | http://ies.ijo.cn/cn_publish/2019/3/201903021.pdf |
id |
doaj-85767db7903b4bd4bd4092118c6a8980 |
---|---|
record_format |
Article |
spelling |
doaj-85767db7903b4bd4bd4092118c6a89802020-11-24T20:45:02ZengPress of International Journal of Ophthalmology (IJO PRESS)Guoji Yanke Zazhi1672-51231672-51232019-03-0119343844110.3980/j.issn.1672-5123.2019.3.21Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathyWen Luo0Mei Ming1Department of Ophthalmology, Huangshi Hospital of Traditional Chinese Medicine of the Eastern Hubei Medical Group, Huangshi 435000, Hubei Province, ChinaDepartment of Ophthalmology, Huangshi Hospital of Traditional Chinese Medicine of the Eastern Hubei Medical Group, Huangshi 435000, Hubei Province, ChinaAIM:To discuss the effect of ranibizumab combined with vitrectomy(VT)on the serum vascular endothelial growth factor A(VEGF-A)and human stromal cell derived factor 1(SDF-1)expression in patients with PDR.<p>METHODS: Totally 120 patients with PDR were selected from January 2017 to January 2018 in our hospital, according to the random digital table, they were divided into group A and group B, 60 cases in each group, group A was given VT treatment, group B was given ranibizumab vitreous injection treatment on this basis, the VT operation, complication and VEGF-A, SDF-1, BCVA, CMT were compared between the two groups.<p>RESULTS: The postoperative serum VEGF-A and SDF-1 levels in the two groups were significantly lower than those in the preoperative, and the group B was significantly lower than group A(<i>P</i><0.05). The VT operation time, electrocoagulation, intraoperative bleeding and complication rate in the group B were significantly lower than those in the group A(<i>P</i><0.05). The 1d, 3mo postoperative BCVA, CMT in the two groups were significantly lower than those in the preoperative, and the group B was significantly lower than the group A(<i>P</i><0.05).<p>CONCLUSION: ranibizumab combined with VT can effectively improve the serum VEGF-A and SDF-1 levels in patients with PDR, it can reduce the trauma and complications of VT, and improve the BCVA and CMT in patient.http://ies.ijo.cn/cn_publish/2019/3/201903021.pdfranibizumabvitrectomyproliferative diabetic retinopathyvascular endothelial growth factorhuman stromal cell derived factor 1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wen Luo Mei Ming |
spellingShingle |
Wen Luo Mei Ming Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathy Guoji Yanke Zazhi ranibizumab vitrectomy proliferative diabetic retinopathy vascular endothelial growth factor human stromal cell derived factor 1 |
author_facet |
Wen Luo Mei Ming |
author_sort |
Wen Luo |
title |
Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathy |
title_short |
Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathy |
title_full |
Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathy |
title_fullStr |
Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathy |
title_full_unstemmed |
Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathy |
title_sort |
effect of ranibizumab combined with vitrectomy on the serum vegf-a and sdf-1 expression in patients with proliferative diabetic retinopathy |
publisher |
Press of International Journal of Ophthalmology (IJO PRESS) |
series |
Guoji Yanke Zazhi |
issn |
1672-5123 1672-5123 |
publishDate |
2019-03-01 |
description |
AIM:To discuss the effect of ranibizumab combined with vitrectomy(VT)on the serum vascular endothelial growth factor A(VEGF-A)and human stromal cell derived factor 1(SDF-1)expression in patients with PDR.<p>METHODS: Totally 120 patients with PDR were selected from January 2017 to January 2018 in our hospital, according to the random digital table, they were divided into group A and group B, 60 cases in each group, group A was given VT treatment, group B was given ranibizumab vitreous injection treatment on this basis, the VT operation, complication and VEGF-A, SDF-1, BCVA, CMT were compared between the two groups.<p>RESULTS: The postoperative serum VEGF-A and SDF-1 levels in the two groups were significantly lower than those in the preoperative, and the group B was significantly lower than group A(<i>P</i><0.05). The VT operation time, electrocoagulation, intraoperative bleeding and complication rate in the group B were significantly lower than those in the group A(<i>P</i><0.05). The 1d, 3mo postoperative BCVA, CMT in the two groups were significantly lower than those in the preoperative, and the group B was significantly lower than the group A(<i>P</i><0.05).<p>CONCLUSION: ranibizumab combined with VT can effectively improve the serum VEGF-A and SDF-1 levels in patients with PDR, it can reduce the trauma and complications of VT, and improve the BCVA and CMT in patient. |
topic |
ranibizumab vitrectomy proliferative diabetic retinopathy vascular endothelial growth factor human stromal cell derived factor 1 |
url |
http://ies.ijo.cn/cn_publish/2019/3/201903021.pdf |
work_keys_str_mv |
AT wenluo effectofranibizumabcombinedwithvitrectomyontheserumvegfaandsdf1expressioninpatientswithproliferativediabeticretinopathy AT meiming effectofranibizumabcombinedwithvitrectomyontheserumvegfaandsdf1expressioninpatientswithproliferativediabeticretinopathy |
_version_ |
1716815744796196864 |